This month, Oxeia Biopharmaceuticals will be launching their Phase 2 trials of their drug treatment for concussion, OXE-103, a synthetic form of the hormone ghrelin. CEO MIchael Wyand discusses the challenges of being the first potential drug for concussion to go through the FDA review process, and more.

Melissa Martin, a former cheerleader at the University of California at Berkeley, has filed a lawsuit against the school, her coaches, and USA Cheer, for negligent treatment after being diagnosed with post-concussion syndrome.